We used UALCAN to profile EPH expression in different pathological stages of UVM and found that the patients with metastatic disease (Stage 4) had significantly different levels of EPH receptors compared to Stage 3 patients. This evidence concerns the gene EPHA1 and metastatic neoplasm.